New blood test may spot deadly pneumonia in ventilator patients earlier

NCT ID NCT06993623

Not yet recruiting Diagnosis Sponsor: Esraa Hamdy Thabit Riad Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study will enroll 80 adults on ventilators for at least 48 hours who develop pneumonia. Researchers will measure a protein called heparin-binding protein (HBP) in the blood and compare it to standard platelet tests to see which better predicts survival and recovery. The goal is to find a more reliable way to guide treatment decisions for this serious complication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: heparin-binding protein (HBP) blood test
What this could lead to: If HBP proves reliable, it could give doctors a faster, more accurate way to diagnose and predict recovery from ventilator-associated pneumonia.
What could go wrong: This is a small, early-stage study (80 patients) that only measures biomarkers, not a treatment. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTILATOR-ASSOCIATED PNEUMONIA (VAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTILATOR-ASSOCIATED PNEUMONIA (VAP)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Minia university Hospitals

Minya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.